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SUMMARY
Immune responses may arrest tumor growth by inducing tumor dormancy. The mechanisms leading to either
tumor dormancy or promotion of multistage carcinogenesis by adaptive immunity are poorly characterized.
Analyzing T antigen (Tag)-induced multistage carcinogenesis in pancreatic islets, we show that Tag-specific
CD4+ T cells home selectively into the tumor microenvironment around the islets, where they either arrest or
promote transition of dysplastic islets into islet carcinomas. Through combined TNFR1 signaling and IFN-g
signaling, Tag-specific CD4+ T cells induce antiangiogenic chemokines and prevent avb3 integrin expression,
tumor angiogenesis, tumor cell proliferation, and multistage carcinogenesis, without destroying Tag-ex-
pressing islet cells. In the absence of either TNFR1 signaling or IFN-g signaling, the same T cells paradoxically
promote angiogenesis and multistage carcinogenesis. Thus, tumor-specific T cells can directly survey mul-
tistage carcinogenesis through cytokine signaling.INTRODUCTION
Malignant tumors evolve along multistage programs that require
establishment of a tumor stroma, neoangiogenesis, and reprog-
ramming of cell metabolism, leading to the expression of tumor-associated antigens (TAA) (Bissell and Radisky, 2001; Boon
et al., 2006; Folkman et al., 1989; Hanahan and Weinberg,
2000). This program is influenced by innate immune cells that
promote aberrant growth of the avb3 integrin-expressing ves-
sels, required for the transition of premalignant dysplasias intoSIGNIFICANCE
Previous studies revealed that CD4+ T cells reject transplanted tumors better than cytotoxic CD8+ T cells, but the effects of
CD4+ T cells on multistage carcinogenesis remain enigmatic. Studying the effects of tumor-specific, IFN-g-producing CD4+
T cells on T antigen-driven multistage carcinogenesis, we found that T cells can either arrest or promote multistage carci-
nogenesis through cytokine signaling. Arresting multistage carcinogenesis strictly requires concerted IFN-g signaling and
TNFR1 signaling; if either signaling is impaired, the same T cells significantly promote angiogenesis and multistage carci-
nogenesis. The data show that tumor-specific T cells can directly affect multistage carcinogenesis and characterize the
tightly regulated cytokine interactions that determine whether a specific T cell response arrests or accelerates progression
from premalignant dysplasia into cancer.Cancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc. 507
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Th1 Cell-Mediated Tumor Dormancycarcinomas and further cancer progression (Arnott et al., 2004;
Bergers et al., 2000; Bhowmick et al., 2004; de Visser et al.,
2006; Lin et al., 2001; Moore et al., 1999; Nozawa et al., 2006;
Soucek et al., 2007; Suganuma et al., 1999).
Adaptive immune responses against TAA may also influence
carcinogenesis. T and B cell (RAG/)- or interferon g receptor
(IFN-gR/)- deficient mice have a 10-fold increase in infec-
tion-associated malignancies, but not of other malignancies
(Shankaran et al., 2001; Street et al., 2002). T cells and IFN-g
may arrest certain established tumors in mice and probably
also in humans (Koebel et al., 2007; MacKie et al., 2003; Sato
et al., 2005), and certain vaccine protocols protect mice even
against tumors that develop under a strong transgenic tumor
promotor (Holmgren et al., 2006; Nanni et al., 2001; Pannellini
et al., 2006; Willimsky and Blankenstein, 2005). Yet, the molecu-
lar mechanisms underlying the T cell-mediated control of multi-
stage carcinogenesis remain unknown.
Most work focused on cytolytic CD8+ T cells (CTL). But the role
of CTL in tumor cell killing under clinical conditions is still not un-
derstood, as strong TAA-specific CTL responses don’t correlate
with effective tumor protection (Nelson et al., 2001; Valmori et al.,
2001; Willimsky and Blankenstein, 2005; Yee et al., 2002). Even
though CTL can eradicate freshly transplanted tumor cells, nu-
merous data suggest that IFN-g-producing CD4+ T cells (Th1)
prevent growth and development of transplanted tumors more
efficiently than CTL. As CD4+ T cells cannot recognize major his-
tocompatibility complex (MHC) class II-negative tumor cells, Th1
cells may provide bystander help for CTL, induce cytotoxic mac-
rophages, affect tumor cell differentiation or tumor stroma, or in-
hibit vessel formation (Chamoto et al., 2006; Daniel et al., 2005;
Ganss et al., 2002; Greenberg, 1991; Mocikat et al., 2003; Mum-
berg et al., 1999; Nishikawa et al., 2005; Qin and Blankenstein,
2000; Rosenberg et al., 2004).
Most insights into tumor immunology result from transplanted
monoclonal tumors that do not follow the events of multistage
carcinogenesis. To investigate the effects of TAA-specific CD4+
T cells on endogenous, multistage carcinogenesis, we analyzed
mice that express T antigen (Tag) under the control of the rat
insulin promoter (RIP1-Tag2). Tag inhibits the tumor suppressors
p53 and retinoblastoma protein (Rb) (Casanovas et al., 2005a).
RIP1-Tag2 mice develop islet adenomas with new avb3 integrin-
expressing blood vessels of abnormal configuration in 20% of
the islets. Within 6 weeks, two to five of those adenomas progress
into carcinomas (Bergers et al., 1999; Casanovas et al., 2005b).
Here we show that Tag-specific CD4+ T cells expressing
a T cell receptor (TCR) specific for Tag peptide 362-384 (TCR2;
Forster et al., 1995) directly regulate multistage carcinogenesis
through cytokine signals. Tag-specific Th1 cells induced a state
of tumor dormancy. Paradoxically, in the absence of either IFN-g
signaling or tumor necrosis factor p55 receptor (TNFR1) signal-
ing the same Tag-specific Th1 cells strongly promoted multi-
stage carcinogenesis.
RESULTS
Selective Homing of Tag-Specific CD4+ T Cells
into the Peritumoral Microenvironment
To study the impact of TAA-specific CD4+ T cells on multistage
carcinogenesis in endogenous tumors, we transferred IFN-508 Cancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc.g-producing, Tag-specific Th1 cells into RIP1-Tag2 mice that
express the Tag oncogene in all islet cells. CD4+ TCR2 cells spe-
cific for Tag peptide 362–384 were stimulated in vitro with Tag
peptide 362-384, CpG-oligonucleotide 1668, and antigen-pre-
senting cells (APC) to generate Th1 cells. After 1 week, >95%
cells expressed the idiotypic TCR2 and produced IFN-g but no
interleukin (IL-) 4 (Figure 1A). They were termed Tag-Th1 cells.
Figure 1. Specific Homing of Tag-Th1 Cells into the Tumor Micro-
environment and the Tumor-Draining Lymph Node
(A) Intracytoplasmatic staining of Tag-specific Th1 cells isolated from TCR2
mice. After stimulation with ionomycin/PMA, idiotypic TCR expression and
intracellular cytokine load were determined by FACS.
(B) (Top) Fluorescence images of pancreas and omentum 3 days after i.p. in-
jection of Cy5-labeled Tag-Th1 cells into a RIP1-Tag2 (left) or a C3H wild-type
mouse (right). Red and green colors indicate increased fluorescence from
Tag-Th1 cells. (Bottom) Corresponding bright field images.
(C) Mean ratio of tumor to normal pancreas (background) fluorescence ±
SD (n = 5) of Cy5-labeled Tag-Th1 cells on day three after i.p. injection into
RIP1-Tag2 mice (black bar) or C3H wild-type littermates (white bar). *p = 0.04.
(D) Mean fluorescence intensity ± SD (n = 5) of liver, spleen, draining, and
distant lymph nodes (LN) from the same experiment as in (C). **p < 0.01.
(E) Immunohistochemistry of CD4+ lymphocytes in the peritumoral microenvi-
ronment of Tag-Th1 cell- (left) or sham-treated (right) RIP1-Tag2 mice.
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Th1 Cell-Mediated Tumor DormancyWe treated 7- to 8-week-old RIP1-Tag2 mice once weekly with
107 Tag-Th1 cells. At this time, about 20% of islets had switched
on angiogenesis, characterized by the presence of avb3-
expressing vessels, and transformed into hyper- or dysplastic
adenomas, which decreased blood glucose to around 90 mg/dl.
These changes precede the transition of dysplastic islets into
carcinomas by 2 weeks.
Tag-Th1 cells were labeled with Cy5 fluorescent dye to follow
their migration in vivo. Within 3 days, intense fluorescence was
detected in the pancreas of RIP1-Tag2 mice but not in that of
C3H controls (Figures 1B and 1C). Fluorescent Tag-Th1 cells
were also enriched specifically in the pancreas-draining lymph
node of RIP1-Tag2 but not in that of nontransgenic C3H mice
(Figure 1D). We also detected Tag-Th1 cells in spleen and mes-
enteric lymph nodes. These Tag-Th1 cells were functional based
on Tag-specific proliferation and IFN-g production. No Tag-
reactive Th1 cells appeared in sham-treated RIP1-Tag2 mice
(Figure S1 available online).
To localize the Tag-Th1 cells more precisely, we performed
autoradiography of labeled Tag-Th1 cells and immune histology.
These analyses revealed homing of Tag-Th1 cells around the
islets, where they established lymph follicle-like structures
(Figure 1E). Infiltration of islets was a rare event.
Tag-Th1 Cells Double Survival Time
without Causing Autoimmune Diabetes
We next analyzed the effects of Tag-Th1 cells on blood glucose
and survival in 7- to 8-week-old mice with established adeno-
mas. Starting from the day of treatment, sham-treated mice lived
8 weeks, while Tag-Th1 treated mice lived up to 16 weeks, which
equals a doubling of the survival time (Figure 2A). Irradiation
alone did not affect survival of RIP1-Tag2 mice (Figure S2). In
RIP1-Tag2 mice, a similar prolongation of life was previously
obtained by treating these mice with in vitro activated, islet
cell-specific CTL that destroyed all insulin-producing cells and
caused severe diabetes (Speiser et al., 1997). In contrast, treat-
ment with Tag-Th1 cells did not cause diabetes in RIP1-Tag2
mice from >10 independent experiments. The mice had slightly
subnormal but stable blood glucose levels (Figure 2B; p <
0.0005). Thus, transfer of ‘‘auto’’-reactive Tag-Th1 cells did not
destroy the Tag-expressing islet cells, as 100% of the cells
express Tag.
We also started treatment with Tag-Th1 cells at earlier stages
of malignant transformation, i.e., at 5 weeks of age, when the
earliest signs of tumor angiogenesis and dysplasia appear.
Under these conditions, Tag-Th1 cells even doubled the total
life span, as half of the mice lived beyond week 30 (Figure 2C).
Again, none of the mice developed diabetes.
Tag-Th1 Cells Arrest Tumor Growth
and Tumor Angiogenesis
To confirm that Tag-Th1 cells arrested tumor growth without
destroying islet cells, we first performed pancreas histology
from 12-week-old C3H, untreated RIP1-Tag2 or RIP1-Tag2
mice treated for 6 weeks with Tag-Th1 cells. The pancreas of
C3H mice harbors small islets (Figure 3A). RIP1-Tag2 mice had
two to three carcinomas with large vascular spaces, the mature
ones surrounded by a-actin-expressing pericytes (Figure 3B).
X-ray treatment alone (2 Gy) did not influence carcinoma develop-ment (Figure 3C). Following treatment with Tag-Th1 cells, tumors
seemed to be arrested at the level of premalignant dysplasia or
adenoma (Figures 3D and 3E). There were few islets with infiltrat-
ing CD4+ and CD8+ T cells, and destruction inside the islets was
rare (Figures 1E and 3E). Islets of Tag-Th1-treated mice had only
very small vessels, and even the somewhat larger adenomas
were almost devoid of vascular structures or a-actin-expressing
pericytes (Figures 3D and 3E).
Tag-Th1 Cells Prevent Aberrant avb3 Activation
and Tumor Vessel Formation
To quantify the histological finding that Tag-Th1 cells prevented
the angiogenic switch and inhibited blood vessel formation, we
first counted tumors and determined tumor size in relation to
the pancreas and the number of CD31+ vessels using morpho-
metric techniques. At week 14, sham-treated RIP1-Tag2 mice
Figure 2. Adoptive Transfer of Tag-Th1 Cells Extends Life of
RIP1-Tag2 Mice without Causing Diabetes
(A) Survival of sham-treated RIP1-Tag2 mice or RIP1-Tag2 mice receiving 107
Tag-Th1 cells once every week (n = 11, p < 0.0005), with treatment starting at
week 7.
(B) Corresponding blood glucose levels of RIP1-Tag2 mice, RIP1-Tag2 mice
receiving Tag-Th1 cells, or C3H wild-type mice. The data show the curves of
one representative experiment.
(C) Survival of sham-treated RIP1-Tag2 mice or RIP1-Tag2 mice receiving 107
Tag-Th1 cells once every week (n = 8, p < 0.001), with treatment starting at
week 5.Cancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc. 509
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prominent angiogenesis. At this time, Tag-Th1 cell-treated mice
had fewer adenomas/tumors (Figure 4A), and the tumors were
significantly smaller (Figure 4B) and also had significantly fewer
vessels than those in sham-treated mice (Figure 4C). CD31 and
a-actin staining revealed that the few vessels developing in ade-
nomas of Tag-Th1 cell-treated mice were small and displayed
normal CD31+ endothelia and pericytes (Figure 4D and data not
shown). In contrast, only part of the tumor vessels in sham-
treated mice expressed both markers of vessel maturation. Large
tumors of sham-treated mice showed numerous immature
Figure 3. Tag-Th1 Cells Prevent Growth of Endogenous Tumors
and Angiogenesis in Transgenic RIP1-Tag2 Mice
(A) H&E staining of pancreas (left) or islets (center), and mature vessels stained
with anti-a-actin antibody (right) from a C3H wild-type mouse treated with
Tag-Th1 cells.
(B and C) H&E staining of pancreas (left), islet carcinomas (center) or a-actin-
staining (right) of an islet carcinoma from an untreated RIP1-Tag2 mouse (B) or
after low-dose irradiation (2 Gy) (C).
(D and E) H&E staining of total pancreas ([D], detail; [E], left) or an infiltrated islet
adenoma ([E], center), or a-actin staining ([E], right) of an islet adenoma from
Tag-Th1 cell-treated RIP1-Tag2 mice with treatment starting at week 7.
(A–E) The age of the mice was 12 weeks ± 4 days.510 Cancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc.vascular structures devoid of CD31+ endothelia or a-actin+ peri-
cytes and microhemorrhaging (Figure 4D and data not shown).
As vessels sprouting inside tumors strongly express activated
avb3 integrin (Carmeliet and Jain, 2000), we determined the pres-
ence and distribution of b3 integrin by immunohistology. The b3
integrin staining was restricted to endothelia lining vessels inside
the carcinomas, and tumor cells did not express b3 integrin (Fig-
ures 5A and 5B). b3 integrin
+ endothelia established large tubules
in tumors of sham-treated mice, while b3 integrin
+ vessels were
rare and very small in islets of RIP1-Tag2 mice treated with
Tag-Th1 cells (Figure 5B). Thus, the analysis of avb3 integrin
expression inside the tumor vessels provides the opportunity
to quantify active tumor angiogenesis.
We addressed this question with Gluco-RGD, a pentapeptide
that selectively binds with high affinity to activated avb3 integrin
(Haubner et al., 2001; Pfaff et al., 1994). In agreement with the
early angiogenesis seen in histology, [125I]Gluco-RGD uptake
was slightly increased in some of the premalignant dysplasias
of 7-week-old RIP1-Tag2 mice (Figures 5C and 5D). During
the following 3 weeks, [125I]Gluco-RGD uptake increased 4-
to 5-fold and reached a plateau around week 9 (Figure 5D).
Figure 4. Tag-Th1 Cells Prevent Tumor Vessel Growth and the
Angiogenic Switch
(A) Mean values ± SD of tumor counts of sham-treated RIP1-Tag2 mice (white;
n = 18) or Tag-Th1 cell-treated RIP1-Tag2 mice (black; n = 11). *p = 0.002.
(B) Cumulative area of the three largest tumors (mean ± SD) of sham-treated
RIP1-Tag2 mice (white; n = 18) or Tag-Th1-treated RIP1-Tag2 mice (black;
n = 11). **p = 0.006.
(C) Numbers ± SD of CD31+ vessels in ten high-power fields (HPF) in tumors
derived from sham-treated RIP1-Tag2 (white; n = 18) or RIP1-Tag2 mice
treated with Tag-Th1 cells (black; n = 11). ***p < 0.001.
(D) Immunohistochemistry of CD31+ endothelial cells of vessels in sham-
treated (left) or RIP1-Tag2 mice treated with Tag-Th1 cells (right). Arrows point
to CD31+ small vessels. Age: 13 weeks.
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(Figure 5C), and its binding to avb3 was receptor specific, as it
was blocked by pretreatment with unlabeled c(RGDfV) peptide
(Figure 5D). In contrast to sham-treated mice, avb3 integrin
activation was almost prevented in islets of mice treated with
Tag-Th1 cells (Figures 5C and 5D). At 9 to 12 weeks of age,
[125I]Gluco-RGD binding in these mice stayed at the starting level
of untreated, 7-week-old mice (Figures 5C and 5D), demonstrat-
ing that Tag-Th1 cells arrested tumor angiogenesis. Tag-Th1
cells did not affect [125I]Gluco-RGD uptake in any other tissue,
such as the gut (data not shown).
Figure 5. Tag-Th1 Cells Prevent Development of Integrin
avb3-Expressing Endothelial Cells and Tumor Vessels
(A) Immunohistochemistry of tumor vessel-lining endothelia with b3 mAb (left)
or isotype control (right) in a RIP1-Tag2 mouse (12 weeks).
(B) b3-immunohistochemistry of tumor vessels in a RIP1-Tag2 mouse (8
weeks) treated with Tag-Th1 cells (top) or an untreated RIP1-Tag2 (bottom).
(C) Phosphor storage autoradiography of the pancreas of a C3H (7 weeks),
a RIP1-Tag2 (7 weeks), an untreated RIP1-Tag2 (12 weeks), and a RIP1-
Tag2 mouse (12 weeks) treated with Tag-Th1 cells. The autoradiography
was performed 3 hr after injection of 370 kBq [125I]Gluco-RGD.
(D) Mean radiation intensity of [125I]-Gluco RGD uptake in pancreata of C3H,
untreated RIP1-Tag2 and RIP1-Tag2 mice treated with Tag-Th1 cells (n = 3).
Selectivity was demonstrated by blocking [125I]-Gluco-RGD uptake with
unlabeled c(RGDfV) peptide.Tag-Th1 Cells Arrest Tumor Cell Proliferation
without Destroying TAA-Expressing Islets
To exclude that inhibition of angiogenesis resulted from tumor
cell destruction by CTL that were activated by Tag-Th1 cells,
we deleted >98% CD8+ cells by weekly injection of monoclonal
antibody (mAb) RmCD8-2 (Egeter et al., 2000), starting 1 week
before therapy. Even in the absence of CTL, [125I]Gluco-RGD
uptake remained at background levels in Tag-Th1 cell-treated
mice (Figures 6A and 6B), demonstrating that inhibition of tumor
angiogenesis by Tag-Th1 cells was CTL independent.
Th1 cells might also control tumor growth by inducing exten-
sive apoptosis of TAA-expressing tumor cells or of endothelia
lining the tumor vessels through IFN-g- and TNF-mediated sig-
nals. We therefore analyzed the number of apoptotic tumor cells
or endothelial cells in Tag-Th1 cell-treated or untreated RIP1-
Tag2 mice at week 8, the time when carcinomas start to develop
in untreated RIP1-Tag2 mice. Most islets or endothelia of
untreated RIP1-Tag2 mice displayed only few apoptotic cells
(3.4% ± 0.9% [n = 4] TUNEL+ islet cells). Importantly, Tag-Th1
cell-treated mice did not show a significant increase in apoptotic
cells (2.7% ± 0.6% [n = 4] TUNEL+ islet cells; for TUNEL staining
of islets see Figure 6C). Thus, apoptosis induction is unlikely to
account for the therapeutic effect of Tag-Th1 cells.
Alternatively, Tag-Th1 cells may inhibit tumor cell proliferation.
To address this question, BrdU was injected into mice, and the
pancreas was stained to quantify proliferating b cells. Tumor-
bearing mice had strongly increased numbers of BrdU+ cells
as compared to C3H mice (Figure 6D). Treatment with Tag-Th1
cells significantly reduced BrdU+ tumor cells (Figure 6D), while
irradiation alone did not.
In the Absence of Tightly Coordinated IFN-g
and TNF Interactions, Tag-Th1 Cells Promote
Tumor Growth and Angiogenesis
Proinflammatory in vivo functions of Th1 cells strictly depend on
the coordinated interaction of IFN-g and TNF (Abbas et al.,
1996). Based on this observation, we treated RIP1-Tag2 mice
with Tag-Th1 cells in the presence of anti-IFN-g mAb or control
mAb. In the absence of Tag-Th1 cells, anti-IFN-g mAb had no
clear effects on tumor growth (Figure S3). In sharp contrast,
when we injected identical doses of anti-IFN-g together with
Tag-Th1 cells, decline of blood glucose and death occurred as
rapidly as in sham-treated mice (Figure 7A; Figure S4). Anti-
IFN-g did not delete Tag-Th1 cells, as spleens of anti-IFN-g-
treated mice had normal numbers of idiotypic Tag-Th1 cells (Fig-
ure 7B) that produced decreased amounts of IFN-g. In the pres-
ence of anti-IFN-g, fluorescence-labeled Tag-Th1 cells homed
normally into the pancreas and draining lymph node of RIP1-
Tag2 mice (Figure S5). At 14 weeks, mice treated by a combina-
tion of Tag-Th1 cells and anti-IFN-g had a 2-fold greater tumor
burden than untreated mice due to increased tumor size (Figures
7C and 7D). Increased tumor size closely correlated with signif-
icantly increased tumor vessel density (Figure 7E). In some mice,
tumor vessels grew so rapidly that islet carcinomas protruded
into the abdomen (Figure 7C) or caused metastasis, phenomena
that we never observed in more than 100 sham-treated RIP1-
Tag2 mice.
Then, we analyzed the effects of IFN-g on interferon-inducible
protein 10 (IP10; CXCL10) or monokine-induced by IFN-g (Mig;
Cancer Cell
Th1 Cell-Mediated Tumor DormancyCXCL9), two potent angiogenesis inhibitors (Tannenbaum et al.,
1998). On week 14, the pancreas of Tag-Th1 cell-treated mice
expressed 10-fold higher mRNA levels of CXCL9 and CXCL10
than the pancreas from C3H or sham-treated RIP1-Tag2 mice
(Figure 7F). In the presence of anti-IFN-g, Tag-Th1 cells failed
to induce either CXCL9 or CXCL10 (Figure 7F), showing that
Tag-Th1 cells induced the two chemokines through an IFN-g-de-
pendent mechanism. In contrast, mRNA levels of vascular endo-
Figure 6. Inhibition ofMultistageCarcinogenesis by Tag-Th1Cells Is
Independent of Host CD8-Positive Cells and Tumor Cell Apoptosis
but Reduces Proliferation inside Adenomas
(A) Phosphor storage autoradiography of pancreata of CD8-depleted RIP1-
Tag2 mice (15 weeks). Mice were untreated or received weekly injections of
Tag-Th1 cells.
(B) Corresponding mean radiation intensity of [125I]Gluco-RGD uptake in pan-
creata of untreated RIP1-Tag2 (left) or RIP1-Tag2 mice treated with Tag-Th1
cells (right). Two independent experiments are shown.
(C) TUNEL (brown) and a-actin staining (red) of insulinomas at 8 weeks of
Tag-Th1 cell-treated (right, 2 weeks of treatment) or sham-treated RIP1-
Tag2 mice (left).
(D) BrdU+ cells in % ± SD (n = 4) in islets of controls (nontransgenic mice, left
bar), or sham-treated RIP1-Tag2 mice with or without additional X-ray treat-
ment, or RIP1-Tag2 mice treated with Tag-Th1 lymphocytes. *p = 0.03; **p =
0.02; n.d. = not detectable. Age: 8 weeks; 2 weeks of treatment.512 Cancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc.thelial growth factor (VEGF) or matrix metallo-proteinase (MMP)9
remained unaffected by Tag-Th1 cells (data not shown).
As the proinflammatory effects of TNF require signaling
through TNFR1, we backcrossed TNFR1/ mice (Pfeffer et al.,
1993) over 12 generations to the C3H background and crossed
them with RIP1-Tag2 mice to generate TNFR1/ 3 RIP1-Tag2
mice. In untreated TNFR1/ 3 RIP1-Tag2 mice, blood glucose
decreased somewhat slower than in normal RIP1-Tag2 mice or
heterozygous TNFR1/+ 3 RIP1-Tag2 mice. Mean survival of
untreated TNFR1/ 3 RIP1-Tag2 mice was also slightly pro-
longed (data not shown), suggesting that TNFR1-mediated
signals facilitate multistage carcinogenesis in RIP1-Tag2 mice.
To study Tag-Th1 cells, we started by imaging Th1 cell migration.
In TNFR1/3RIP1-Tag2 mice, Tag-Th1 cells showed the same
distribution as in TNFR1-expressing mice and survived normally
(Figures S6 and S7).
Surprisingly, when treated with Tag-Th1 cells, TNFR1/ 3
RIP1-Tag2 mice died faster than TNFR1+/+ 3 RIP1-Tag2 mice,
and Tag-Th1 cell-treated TNFR1/ 3 RIP1-Tag2 mice died
even faster than sham-treated TNFR1/ 3 RIP1-Tag2 mice
(Figure 8A). To quantify the enhancement of tumor growth by
Tag-Th1 cells in TNFR1/ 3 RIP1-Tag2 mice, we counted the
islet cells of sham-treated TNFR1/ 3 RIP1-Tag2 mice and of
TNFR1/ 3 RIP1-Tag2 mice treated with Tag-Th1 cells. In
TNFR1/3 RIP1-Tag2 mice, Tag-Th1 cells increased the num-
ber of islet cells 10-fold, as compared to sham-treated mice (Fig-
ure 8B). To determine the reasons of enhanced tumor growth, we
analyzed antiangiogenic chemokines and tumor cell proliferation
in vivo. While Tag-Th1 cells strongly induced the expression of
CXCL9 and CXCL10 in TNFR1-expressing RIP1-Tag2 mice,
both chemokines were at background in Tag-Th1 cell-treated
TNFR1/3RIP1-Tag2 mice (Figure 8C). Finally, we determined
BrdU-labeled cells in Tag-Th1 cell-treated and sham-treated
TNFR1/ 3 RIP1-Tag2 mice. Tag-Th1 cells significantly in-
creased proliferating tumor cells in TNFR1/ 3 RIP1-Tag2
mice (Figure 8D). Thus, the same Tag-Th1 cells that efficiently
suppressed angiogenesis, tumor cell proliferation, and multi-
stage carcinogenesis under normal experimental conditions
strongly promoted Tag-driven tumor development in mice with
impaired IFN-g signaling or TNFR1 signaling.
DISCUSSION
Studying the effects of adaptive immunity on endogenous multi-
stage carcinogenesis developing under the pressure of deregu-
lated p53 and Rb protein, we found that TAA-specific Th1 cells
homed in the peritumoral microenvironment, where they ar-
rested angiogenesis, cell proliferation, and multistage carcino-
genesis. This inhibition was independent of CTL or signs of tumor
cell killing. In the absence of either IFN-g signaling or TNFR1 sig-
naling, the same T cells promoted multistage carcinogenesis.
Both innate and adaptive immune responses exert opposing
effects on the growth of various experimental and human tumors
(Arnott et al., 2004; Daniel et al., 2003; de Visser et al., 2006; Koe-
bel et al., 2007; Lin and Karin, 2007; Moore et al., 1999; Prehn,
1972; Siegel et al., 2000; Schadendorf et al., 2006; Schultz
et al., 2004; Suganuma et al., 2006). However, the conditions dis-
tinguishing tumor promotion from tumor suppression are poorly
understood.
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development require consideration of the tumor analyzed and
the cytokine conditions studied. Transplanted tumors, tumors in-
duced by carcinogens, or tumors developing as a consequence
of deregulated apoptosis and clearance mechanisms may show
opposing effects to immune responses (de Visser et al., 2006).
Thus, calcineurin inhibitors strongly increase the risk of virally
or UV-induced malignancies (Haagsma et al., 2001), while they
may protect against other types of cancer, such as breast cancer
(Stewart et al., 1995).
Similarly, the action of cytokines critically depends on their
concentration, the time of action, the target cell, and their coor-
dination. High TNF doses that act for short periods of time induce
apoptosis of tumor vessels and tumor necrosis, an effect used as
Figure 7. In the Absence of IFN-g, Tag-Th1
Cells Paradoxically Promote Multistage
Carcinogenesis
(A) Blood glucose in Tag-Th1-treated RIP1-Tag2
mice in the presence of blocking anti-IFN-g mAb
(weekly injection of mAb XMG12 [Egeter et al.,
2000]) (n = 5) or control mAb (n = 4, p < 0.005).
(B) FACS analysis of CD4+ and Tag-Th1-idiotype+
cells in spleens of RIP1-Tag2 mice (12 weeks),
treated with Tag-Th1 cells in the presence or
absence of IFN-g mAb (top). (Bottom) Intracyto-
plasmatic IFN-g load of Tag-Th1-idiotype+ spleen
cells.
(C) Overview (left) and high-power field (right) of
H&E-stained islet carcinomas in a RIP1-Tag2
mouse (14 weeks) treated with Tag-Th1 cells and
anti-IFN-g mAb.
(D) Cumulative area of the three largest tumors of
sham-treated RIP1-Tag2 (14 weeks, mean ± SD,
n = 8) or RIP1-Tag2 mice treated with Tag-Th1
and IFN-g antibody (n = 15). *p = 0.02.
(E) Vessel density (number of vessels ± SD) in
Tag-Th1 (n = 3)- or sham (n = 8)-treated RIP1-
Tag2, or in RIP1-Tag2 mice (14 weeks) treated
with Tag-Th1 cells and anti-IFN-gmAb. **p = 0.01.
(F) Quantitative RT-PCR of CXCL9 and CXCL10 in
the indicated groups (n = 4–7) of mice. The white
bar represents C3H. CXCL9 and CXCL10 mRNA
expression were normalized to aldolase. *p =
0.01 for CXCL9, and **p = 0.02 for CXCL10.
therapy for melanoma metastases (Cars-
well et al., 1975; Olieman et al., 1999;
Stoelcker et al., 2000). In contrast, contin-
uous low doses of TNF promote early
steps of tumor development, such as
tumor angiogenesis in chemically or UV-
induced carcinomas (Arnott et al., 2004;
Moore et al., 1999; Suganuma et al.,
1999). In line with this, islet carcinomas
developed slower in TNFR1/ 3 RIP1-
Tag2 mice than in TNFR1-expressing lit-
ters. Yet, in the presence of Tag-Th1
cells, the same signaling defect con-
verted from a tumor-protective into a tu-
mor-promoting property. Similarly, IFN-g
exerts potent antitumor effects under
most conditions. Yet, persistent inflammation mediated by
IFN-g-producing CD4+ T cells promotes the development of
skin tumors in mice expressing the human papilloma virus type
16 early regions gene (Daniel et al., 2003). Moreover, IFN-g
may attenuate its own action by promoting Th1 cell suicide
(Berner et al., 2007).
IFN-g or IFN-g-producing Th1 cells protect against malignan-
cies under many conditions, and multiple mechanisms have
been proposed to mediate the tumor-protective effects of IFN-g.
IFN-g may directly inhibit growth of tumor cells and seems to
enhance the natural tumor immune surveillance against virus-
induced tumors (Billiau, 1996; Boehm et al., 1997; Kaplan
et al., 1998; Koebel et al., 2007; Shankaran et al., 2001; Street
et al., 2002). IFN-g is needed for activation of APC by NK cellsCancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc. 513
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activation of cytotoxic macrophages, and rejection of trans-
planted MHC class II-positive or MHC class II-negative tumor
cells by Th1 cells (Chamoto et al., 2006; Daniel et al., 2005; Ege-
ter et al., 2000; Greenberg, 1991; Qin and Blankenstein, 2000)
Figure 8. In the Absence of TNFR1 Signaling, Tag-Th1Cells Promote
Multistage Carcinogenesis
(A) Survival of sham-treated TNFR1/ 3 RIP1-Tag2 (n = 12), TNFR1/ 3
RIP1-Tag2 mice treated with Tag-Th1 cells (n = 11) or TNFR+/+ 3 RIP1-Tag2
mice treated with Tag-Th1 cells (n = 5). p < 0.001 for the difference in survival
between TNFR1/3RIP1-Tag2 mice and TNFR+/+3RIP1-Tag2 both treated
with Tag-Th1 cells, and p = 0.05 for the difference between sham-treated
TNFR1/ 3 RIP1-Tag2 mice and TNFR1/ 3 RIP1-Tag2 mice treated with
Tag-Th1 cells.
(B) Tumor cell number ± SD (n = 3) after collagenase/trypsin digestion of
pancreata of sham-treated TNFR/ 3 RIP1-Tag2 (black) or TNFR1/ 3
RIP1-Tag2 mice treated with Tag-Th1 cells (white). *p = 0.04.
(C) Quantitative real-time RT-PCR ± SD (n = 3) of CXCL9 and CXCL10 in
the indicated groups of mice. CXCL9 and CXCL10 mRNA expression were
normalized to aldolase.
(D) BrdU+ cells in % ± SD (n = 4) in islets of TNFR1/ 3 RIP1-Tag2 mice
treated with Tag-Th1 lymphocytes or sham-treated TNFR1/ 3 RIP1-Tag2
mice, or in islets of single transgenic TNFR1/ mice (n.d. = not detectable).
*p = 0.03.514 Cancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc.and can prevent vessel outgrowth from the host stroma into
transplanted tumors (Qin and Blankenstein, 2000; Spiotto
et al., 2004). IFN-g may also interfere with signal cascades that
are involved in malignant transformation, such as c-Myc-,
p53-, or Rb-dependent pathways (Agrawal et al., 2002; Ramana
et al., 2000). Yet, the effects of IFN-g- and TAA-specific Th1 cells
on the various steps of multistage carcinogenesis are poorly
understood. It seems that TAA-specific Th1 responses are
most effective if induced prior to or at very early stages of tumor
development (Holmgren et al., 2006; Nanni et al., 2001; Pannel-
lini et al., 2006; Willimsky and Blankenstein, 2005).
In a functionally related but biologically different tumor model,
the RIP1-Tag5 mouse, control of tumor growth by CTL-mediated
tumor cell killing is followed by restoration of normal blood ves-
sels in the pancreatic islets. These data suggest a direct relation
between tumor cell destruction by CTL and vessel architecture
(Ganss et al., 2002; Garbi et al., 2004; Otahal et al., 2006). Our re-
sults point toward a fundamentally different interpretation. They
revealed that Tag-Th1 cells inhibited angiogenesis and multi-
stage carcinogenesis without significant tumor cell destruction.
This was surprising, as Th1 cells can induce both apoptosis in
tumor cells (Egeter et al., 2000) and destructive autoimmune dis-
ease (Racke et al., 1994). Molecular analysis of tumors and of the
microenvironment revealed that Th1 cells primarily migrated into
the peritumoral microenvironment, and that neither treatment
with Tag-Th1 cells nor inhibition of TNFR1 or IFN-g signaling
affected VEGF or MMP9 mRNA expression.
The combined action of IFN-g signaling and TNFR1 signaling
was needed to prevent activation of avb3 integrin, tumor-angio-
genesis, and multistage carcinogenesis, at least in part indirectly
through induction of the antiangiogenic chemokines CXCL9 and
CXCL10. One potentially relevant source of the two chemokines
are APC (unpublished data). These angiogenesis inhibitors must
obviously overcome tumor-promoting factors delivered by the
Tag-Th1 cell-mediated inflammation. Possible promoters of tu-
mor angiogenesis delivered during Th1 cell-mediated inflamma-
tion are IL-17, CSF1, TNF, MMP9, or VEGF. This interpretation of
Th1 cell action on tumor development is in agreement with the
observation that accelerating the angiogenic switch also accel-
erates multistage carcinogenesis (Inoue et al., 2002). Thus, our
findings are best conceivable with a model in which the com-
bined action of IFN-g signaling (Indraccolo et al., 2007) and
TNFR1 signaling on endothelia induces tumor dormancy at least
in part through antiangiogenic chemokines that arrest or delay
tumor angiogenesis and subsequent multistage carcinogenesis,
even in the presence of VEGF and MMP9. The role of Th1 cells in
preventing multistage carcinogenesis is more complex than sim-
ple inhibition of avb3 integrin activation by the combined delivery
of TNF and IFN-g (Ruegg et al., 1998).
To precisely follow tumor angiogenesis, we studied vessel
formation and tumor development by histology, immune histol-
ogy, and objectively quantified activated avb3 integrin, utilizing
Gluco-RGD that binds with high affinity selectively to activated
avb3 integrin (Haubner et al., 2001; Pfaff et al., 1994). Gluco-
RGD may also bind to a5b1, or aIIb3 integrin, but with much lower
affinity (Haubner et al., 2001; Pfaff et al., 1994). As b1 and b3 integ-
rins are only expressed by endothelia and not by tumor cells (Ba-
luk et al., 2003; Yao et al., 2006), quantitative analysis thus reflects
the extent of active tumor angiogenesis. This quantification
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Th1 Cell-Mediated Tumor Dormancyrevealed that the rate of newly built vessels increased 5-fold dur-
ing the transition of premalignant dysplasias and adenomas into
carcinomas and that Tag-Th1 cells prevented this aberrant acti-
vation of avb3 integrin and tumor angiogenesis.
As in the absence of either IFN-g signaling or TNFR1 signaling
tumor-protective Th1 cells strongly enhanced multistage carci-
nogenesis, future development of tumor immune therapy must
take into account that T cell-derived cytokines can directly inter-
fere with multistage carcinogenesis, or even with the natural de-
velopment of tumors that evolve under the pressure of impaired
tumor suppressors, such as p53 or Rb. The direct impact of our
findings for humans results from recent melanoma vaccine trials,
where protection from metastasis was associated with the ap-
pearance of IFN-g-producing T cells. In the same cohort, metas-
tases expanded more rapidly than in controls, if patients failed to
develop IFN-g-producing T cells (e.g., Schadendorf et al., 2006;
Schultz et al., 2004).
EXPERIMENTAL PROCEDURES
Animals
Animal experiments were approved by the Animal Care Committee (AZ 211-
2531-63/98 and HT 2/03). C3H mice from Charles River (Sulzberg, Germany),
transgenic RIP1-Tag2, double transgenic TNFR1/ 3 RIP1-Tag2 (backcross
of TNFR1/ mice over 12 generations to C3H), and TCR2 mice all on a C3H
background were bred under specific pathogen-free conditions.
Cell Culture and Single-Cell Analysis
CD4+ T cells were isolated from TCR2 mice and cultured for 1 week with Tag
peptide 362-384, CpG-DNA 1668, and anti-IL-4 mAb to induce Th1 cells as
described (Egeter et al., 2000). Cells were restimulated with ionomycin and
phorbol-myristate-acetate (Sigma, Munich, Germany) in vitro in the presence
of brefeldin A (PharMingen, Heidelberg, Germany). Surface staining with fluo-
rescein-labeled mAb to the TCR idiotype and intracellular staining with phyco-
erythrin-labeled mAb to IL-4 or IFN-g or isotype controls (PharMingen) was
done according to the manufacturer’s protocol. Cells were analyzed on a BD
FACScan cytometer (Becton Dickinson [BD], Heidelberg, Germany).
Treatment with Radiation and Tag-Th1 Cells
Before the first therapy and thereafter every 4–6 weeks, all mice received 2 Gy
total-body irradiation. Sham-treated mice received 0.9% NaCl solution, while
Tag-Th1 cell-treated RIP1-Tag2 mice received 107 Tag-Th1 cells in 0.9%
NaCl/week intraperitoneally starting at week 5 or 7. CD8 cells were depleted,
and IFN-g was blocked by weekly injection of mAbs as described (Mocikat
et al., 2003). CD8+ cells were reduced >98%.
Determination of Blood Glucose
Blood glucose was determined using an Eppendorf EBIO plus Glucose-
Analyzer (Eppendorf, Hamburg, Germany).
Isolation of Insulinomas
After collagenase digestion (1 mg/ml; Serva, Heidelberg, Germany) for 10 min
at 37C, islets were isolated from exocrine tissue under binoculars.
BrdU Labeling
For identification of proliferating cells, RIP1-Tag2 mice were injected with 200
mg/kg body weight BrdU (Sigma) and sacrificed 1–2 hr later. Paraffin-embed-
ded slides were deparaffinized and hydrated in graded alcohols. Slides were
then boiled in a antigen retrieval solution (BD) and incubated overnight with
rat anti-BrdU mAb (BD) at a dilution of 1:10 for 1 hr at 23C. Slides were rinsed
with PBS and treated with streptavidin-horseradish-peroxidase (BD) for
30 min. After rinsing, slides were treated with 3,30-diaminobenzidine (DAKO,
Hamburg, Germany) for up to 10 min. Slides were counterstained in hematox-
ylin and mounted under a glass coverslip. Cells labeled with BrdU displayedbrown nuclear stain (positive control: duodenum from mice; negative controls:
insulinomas incubated with a nonspecific antibody).
For quantitation, a minimum of 1000 b cells per mouse were evaluated and
individual tumors were counted separately.
Histology and Immunohistology
Serial paraffin or cryostat sections (5–7 mm) were stained with hematoxylin and
eosin (H&E), mAb to a-actin (Roche, Mannheim, Germany), b3 integrin (Phar-
Mingen), CD31 (PharMingen), or isotype Ab (Roche and PharMingen) as de-
scribed (Biedermann et al., 2001). The scale was either measured or estimated
and given in micrometers. TdT-mediated dUPT nick end labeling (TUNEL)
staining was performed using the ApopTag apoptosis kit (Serologicals,
Norcross, CA).
Quantitation of Vessel Density
The number of CD31-positive vessels (vessel density) or a-actin-positive ves-
sels was counted in three tumors per pancreas. For determination of a-actin-
and CD31-negative tumor blood vessels, all vessels with a lumenR0.02 mm
were counted (n = 3 tumors/mouse).
Assessment of Tumor Burden and Tumor Numbers
Cryostat sections (5 mm) were obtained from snap-frozen pancreata. Sections
were H&E stained. Length and width of each pancreas tumor were measured
microscopically. The formula 0.5 width3 0.5 length3 p for approximating the
area was applied, and the sum of the three largest tumor areas per pancreas
was given.
Molecular Analysis
Tissues were mechanically homogenized in lysis buffer (RNeasy kit; QIAGEN,
Hilden, Germany). During RNA purification genomic DNA was digested with
RNAase-free DNAase (QIAGEN). Total RNA (2 mg) were reverse transcribed
(Omniscript RT-kit, QIAGEN). For each primer pair a standard curve was devel-
oped, and mRNA expression levels were determined by real-time PCR and
normalized with the expression level of aldolase. The following primers were
used: Aldolase (amplicon length 571 bp): FP, 50-AGCTGTCTGACATCGCTCA
CCG; RP, 50-CACATACTGGCAGCGCTTCAAG; CXCL9 (256 bp): FP, 50-TCCC
TCTCGCAAGGACGGTC; RP, 50-GTGTGTGCGTGGCTTCACTC; CXCL10
(280 bp): FP, 50-GCTCCTGCATCAGCACCAGC; RP, 50-CTTGAACGACGACG
ACTTTGG.
Fluorescence Cell Labeling and Imaging
Tag-Th1 cells (106) were labeled with 5 ml Cy5 fluorescent dye (Vibrant DiD cell
labeling solution, Molecular Probes, Leiden, The Netherlands). Whole organ
fluorescence of the pancreas and lymph nodes was imaged using a cooled
ORCA-II-ER coupled charged device (CCD) camera (Hamamatsu, Hama-
matsu, Japan). Bright-field images were performed with a photo camera
(AE1, Canon, Krefeld, Germany). For quantitative fluorescence analysis, pan-
creata, lymph nodes, liver, and spleen were frozen in OCT compound (Tissue
Tek, Vogel, Germany), and 20 mm cryostat sections were analyzed using
a Storm Phosphor Imager (Amersham Bioscience, Sunnyvale, CA) in fluores-
cence mode. Quantitative analysis (focus to background ratio) of infiltrating
Cy5-labeled Tag-Th1 cells was performed with ImageQuant 5.1 software
(Amersham Bioscience) by comparing regions of interest in normal pancreatic
tissue with regions of the same size with highest uptake.
Phosphor Storage Autoradiography
Three hours after i.v. injection of 370 kBq [125I]Gluco-RGD, animals were sac-
rificed and tissue was isolated. Autoradiograms of the pancreas (20 mm fresh
frozen sections) were obtained using a PhosphorImager 445SI (Amersham
Bioscience). Quantitative analysis of [125I]Gluco-RGD uptake (focus to back-
ground ratio) was performed with ImageQuant 5.1 software as described
above.
Statistical Analysis
For statistical analysis of blood glucose levels in different groups, the mean
value for each group and week was used to calculate linear regression curves.
The respective slopes were then compared by t testing. In all groups, the var-
iation of the two blood glucose measurements per mouse in the same weekCancer Cell 13, 507–518, June 2008 ª2008 Elsevier Inc. 515
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Statistical analysis of survival and autoradiography data was performed with
the Mann-Whitney-Wilcoxon test. Statistical analysis of tumor burden, tumor
frequency, and tumor vessel density was performed with the Student’s
t test. p < 0.05 was considered statistically significant.
SUPPLEMENTAL DATA
The Supplemental Data include seven supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/13/6/507/
DC1/.
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